Simona Caraiola1,2, Ciprian Jurcut3, Alina Dima1,2, Ruxandra Jurcut4, Cristian Baicus1,2, Anda Baicus1,5. 1. Department of Internal Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 2. Department of Internal Medicine, Colentina Clinical Hospital, Bucharest, Romania. 3. Department of Internal Medicine, Dr Carol Davila Central University Emergency Military Hospital, Bucharest, Romania. 4. Department of Cardiology, Prof Dr CC Iliescu Institute of Cardiovascular Diseases, Bucharest, Romania. 5. Immunology Laboratory, University Emergency Hospital, Bucharest, Romania.
Abstract
INTRODUCTION: The patients with antiphospholipid syndrome (APS) associate an increased risk of atherosclerosis. OBJECTIVE: To determine the predictors of an abnormal ankle-brachial index (ABI), surrogate measure of atherosclerosis, in patients with APS. METHODS: The ABI was measured according to standard recommendations in 106 patients. Traditional cardiovascular risk factors were assessed in all cases. A large spectrum of APS antibodies was determined in 73 patients. RESULTS: A total of 106 patients diagnosed with APS were included. 28.3% patients included were found to have low ABI. Anti-beta 2-glycoprotein I (aβ2GPI) IgG antibodies [4.00 (1.00-79.00) vs 3.00 (0.00-29.00) U/mL, P = 0.02] and antiprothrombin (aPT) IgM antibodies [4.50 (0.00-82.00) vs 3.00 (0.00-14.00) U/mL, P = 0.05] titers were found to be higher in patients with abnormal ABI. However, after multivariate regression analysis, only the aβ2GPI IgG titer remained predictor of low ABI (P = 0.04). CONCLUSIONS: aβ2GPI IgG associated with impaired ABI in patients with APS. This relation might reflect their involvement in the atherosclerosis occurrence.
INTRODUCTION: The patients with antiphospholipid syndrome (APS) associate an increased risk of atherosclerosis. OBJECTIVE: To determine the predictors of an abnormal ankle-brachial index (ABI), surrogate measure of atherosclerosis, in patients with APS. METHODS: The ABI was measured according to standard recommendations in 106 patients. Traditional cardiovascular risk factors were assessed in all cases. A large spectrum of APS antibodies was determined in 73 patients. RESULTS: A total of 106 patients diagnosed with APS were included. 28.3% patients included were found to have low ABI. Anti-beta 2-glycoprotein I (aβ2GPI) IgG antibodies [4.00 (1.00-79.00) vs 3.00 (0.00-29.00) U/mL, P = 0.02] and antiprothrombin (aPT) IgM antibodies [4.50 (0.00-82.00) vs 3.00 (0.00-14.00) U/mL, P = 0.05] titers were found to be higher in patients with abnormal ABI. However, after multivariate regression analysis, only the aβ2GPI IgG titer remained predictor of low ABI (P = 0.04). CONCLUSIONS: aβ2GPI IgG associated with impaired ABI in patients with APS. This relation might reflect their involvement in the atherosclerosis occurrence.
Authors: C Christodoulou; M Zain; M L Bertolaccini; S Sangle; M A Khamashta; G R V Hughes; D P D'Cruz Journal: Ann Rheum Dis Date: 2006-05 Impact factor: 19.103
Authors: Pál Soltész; György Kerekes; Henriett Dér; Gabriella Szücs; Sándor Szántó; Emese Kiss; Edit Bodolay; Margit Zeher; Orsolya Timár; Péter Szodoray; Gyula Szegedi; Zoltán Szekanecz Journal: Autoimmun Rev Date: 2011-01-31 Impact factor: 9.754
Authors: M Jiménez; L Dorado; M Hernández-Pérez; M T Alzamora; G Pera; P Torán; M Gomis; N Pérez de la Ossa; M Millán; D Escudero; A Dávalos; J F Arenillas; E López-Cancio Journal: Atherosclerosis Date: 2014-01-04 Impact factor: 5.162
Authors: Alina Dima; Simona Caraiola; C Jurcut; Eugenia Balanescu; P Balanescu; Doina Ramba; Camelia Badea; V Pompilian; R Ionescu; Anda Baicus; C Baicus; G A Dan Journal: Rom J Intern Med Date: 2015 Oct-Dec